These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1100 related articles for article (PubMed ID: 17187432)

  • 1. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
    Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
    Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets.
    Katoh H; Ojima H; Kokubu A; Saito S; Kondo T; Kosuge T; Hosoda F; Imoto I; Inazawa J; Hirohashi S; Shibata T
    Gastroenterology; 2007 Nov; 133(5):1475-86. PubMed ID: 17983802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
    Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
    Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
    Xue KX
    Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.
    Ladeiro Y; Couchy G; Balabaud C; Bioulac-Sage P; Pelletier L; Rebouissou S; Zucman-Rossi J
    Hepatology; 2008 Jun; 47(6):1955-63. PubMed ID: 18433021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
    Zucman-Rossi J; Jeannot E; Nhieu JT; Scoazec JY; Guettier C; Rebouissou S; Bacq Y; Leteurtre E; Paradis V; Michalak S; Wendum D; Chiche L; Fabre M; Mellottee L; Laurent C; Partensky C; Castaing D; Zafrani ES; Laurent-Puig P; Balabaud C; Bioulac-Sage P
    Hepatology; 2006 Mar; 43(3):515-24. PubMed ID: 16496320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
    Ishizaki Y; Ikeda S; Fujimori M; Shimizu Y; Kurihara T; Itamoto T; Kikuchi A; Okajima M; Asahara T
    Int J Oncol; 2004 May; 24(5):1077-83. PubMed ID: 15067328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
    Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
    Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
    Yuan RH; Jeng YM; Chen HL; Hsieh FJ; Yang CY; Lee PH; Hsu HC
    Clin Cancer Res; 2005 Apr; 11(7):2568-75. PubMed ID: 15814635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
    Prange W; Breuhahn K; Fischer F; Zilkens C; Pietsch T; Petmecky K; Eilers R; Dienes HP; Schirmacher P
    J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.
    Moriyama Y; Nishiguchi S; Tamori A; Koh N; Yano Y; Kubo S; Hirohashi K; Otani S
    Clin Cancer Res; 2001 May; 7(5):1293-8. PubMed ID: 11350897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells.
    Wu Y; Li J; Sun CY; Zhou Y; Zhao YF; Zhang SJ
    Neoplasma; 2012; 59(3):326-32. PubMed ID: 22296502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.